Abstract
A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n=24) received either 2.5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage*
-
Adolescent
-
Adult
-
Antibodies, Viral / blood
-
Capsid / immunology*
-
Capsid Proteins*
-
Double-Blind Method
-
Humans
-
Immunization Schedule
-
Injections, Intramuscular
-
Middle Aged
-
Neutralization Tests
-
Parvoviridae Infections / blood
-
Parvoviridae Infections / prevention & control*
-
Parvovirus / immunology*
-
Polysorbates / administration & dosage*
-
Squalene / administration & dosage*
-
Vaccination*
-
Vaccines, Synthetic / administration & dosage
-
Viral Vaccines / administration & dosage*
-
Viral Vaccines / immunology*
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Capsid Proteins
-
MF59 oil emulsion
-
Polysorbates
-
Vaccines, Synthetic
-
Viral Vaccines
-
capsid protein VP1, parvovirus B19
-
capsid protein VP2, parvovirus B19
-
Squalene